公司资料
Nemaura Medical 股价、新闻与催化剂
- 股票代码:
- NMRD
- 交易所:
- PINK
- 行业:
- Biopharma
- 所在地:
- United Kingdom and trades in the U
股票表现
0.00 USD (0.00%)
收盘价
最后更新: 2026年10月1日
—
市值
股价为何变动
截至 2026年10月1日，NMRD 股价变化不大，收于 $0.0001。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Non-Invasive Glucose Monitoring Company
Nemaura Medical develops wearable systems intended to measure glucose without penetrating the skin. Its platform is designed for metabolic health, diabetes management, and behavior-change programs.
SugarBEAT Sensor Platform
SugarBEAT uses a small skin-worn sensor and transmitter to collect glucose readings from interstitial fluid. Data are displayed through a mobile application to show glucose patterns and trends throughout the day.
proBEAT Metabolic Program
proBEAT combines glucose data with coaching and digital tools for people with type 2 diabetes or elevated metabolic risk. The service is intended to help users understand how food, activity, and lifestyle affect glucose response.
Device and Subscription Economics
Potential revenue sources include reusable transmitters, disposable sensors, software, coaching subscriptions, and partnerships with healthcare or wellness organizations. Regulatory clearance and reimbursement are important to broader clinical adoption.
未来催化剂
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。